|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Microfluidizer Á¾ÇÕÄ«´Ù·Î±× |
Phone |
|
|
  ´ëÇ¥ÀüÈ |
1577-7956   |
  º»     »ç |
031-457-9187   |
  ´ë     Àü |
042-932-1265 |
|
|
Web Site Visitors |
|
|
  Today |
668     |
  Yesterday |
1161     |
  Since 2006 |
1,941,761     |
|
|
|
|
¿µÁøÄÚÆÛ·¹ÀÌ¼Ç Á¾ÇÕÄ«´Ù·Î±× |
|
|
|
|
Superior Nanoemulsion Production
Microfluidizer¢ç processors ´Â Ãʹ̼¼ droplet ÀÎ nano-emulsion Á¦Á¶¸¦ ¸Å¿ì È¿À²ÀûÀ¸·Î ÇÒ ¼ö ÀÖ´Ù.
product ÀÇ formulation ÀÌ ÁÁÀ¸¸é Microfluidizer¢ç processors °¡ »ý»êÇÏ´Â nano-emulsion Àº Ãʹ̼¼ Å©±âÀÇ droplet ÀÌ°í
droplet ÀÇ size ºÐÆ÷°¡ ¸Å¿ì ±ÕÀÏÇÏ¿© product ÀÇ ¾ÈÁ¤¼ºÀÌ ¸Å¿ì ¶Ù¾î³ª°Ô µÇ°í ¶ÇÇÑ ±× ´ÙÀ½ °øÁ¤¿¡¼ filtration À»
ÇÏ¿©µµ product ÀÇ loss °¡ ±ØÈ÷ Àû´Ù.
Microfluidizer¢ç processors Àåºñ¿¡¼ product ¸¦ ºÐ»ê½ÃÅ°´Â ÀåÄ¡ÀÎ Interaction Chamber ´Â ³»ºÎ ±¸Á¶°¡ °íÁ¤µÇ¾î ÀÖ´Â
fixed geometry ÇüÅ·ΠµÇ¾îÀÖ¾î 󸮿뷮ÀÌ 2ml ÀÎ ½ÇÇè¿ëÀåºñ¿¡¼ ½ÇÇàÇÑ process ¸¦ ½Ã°£´ç ¼ö¹é¸®ÅÍ Ã³¸®ÇÏ´Â ´ëÇüÀåºñ¿¡¼
±×´ë·Î »ç¿ëÇÏ¿©µµ µ¿ÀÏÇÑ °á°ú¸¦ ±¸ÇÒ ¼ö ÀÖ´Ù´Â Å« Ư¡ÀÌ ÀÖ´Ù.
Microfluidizer¢ç processors ´Â »ç¿ëÇϱ⿡ ¸Å¿ì Æí¸®ÇÏ°í cGMP ±ÔÁ¤¿¡ ¿Ïº®È÷ ºÎÇÕµÇ°Ô ¼³°èµÇ¾î ÀÖ´Ù.
Microfluidics ´Â ¼ö½Ê³â°£ ÃàÀûµÈ application °³¹ß ´É·Â°ú Àåºñ °³¹ß ´É·ÂÀ» ¹ÙÅÁÀ¸·Î °í°´¿©·¯ºÐÀÇ Á¦Ç° Ç°ÁúÀ» Çâ»ó½ÃÅ°°í
È¿À²ÀûÀÎ »ý»ê °øÁ¤ °³¹ß¿¡ ÃÖ¼±À» ´ÙÇÏ°í ÀÖ´Ù.
|
|
Why do businesses choose Microfluidics for their nanoemulsion needs? |
Proven Processing Solutions
Vaccine Adjuvant Nanoemulsion Collaboration with the Infectious Disease Research Institute (IDRI)
Unrivaled Uniform Particle Size Reduction
Ãʹ̼¼Å©±âÀÇ nano-emulsion Àº bioavailability ¸¦ Áõ°¡½ÃÅ°°í targeting ´É·ÂÀ» Çâ»ó½ÃŲ´Ù.
¿¹¸¦µé¾î ¾ÏÄ¡·áÁ¦·Î »ç¿ëµÇ´Â nano-emulsion ÀÇ °æ¿ì blood ¿Í brain barrier ¸¦ Åë°úÇÏ¿© ¼¼Æ÷ ³»ºÎ·Î µé¾î°¡´Â ´É·ÂÀÌ ¸Å¿ì Çâ»óµÈ´Ù.
nano-emulsion vaccine adjuvant ÀÇ Á¦Á¶¿¡¼ Microfluidizer¢ç processors ¸¦ ÀÌ¿ëÇÏ¿© ±¸ÇÑ emulsion Àº °°Àº ¿¡³ÊÁö¸¦ »ç¿ëÇÏ´Â Á¶°Ç¿¡¼
´Ù¸¥ ÀÏ¹Ý °í¾ÐºÐ»êÀåºñ¸¦ »ç¿ëÇÏ¿´À» ¶§ º¸´Ù emulsion ÀÇ Å©±â°¡ 18 ~ 55% ´õ ÀÛ¾Ò´Ù.
±×¸®°í ÀÔÀÚ Å©±âÀÇ Ç¥ÁØÆíÂ÷ (standard deviation) ´Â 0.1 ~ 2.6 À¸·Î¼ ´Ù¸¥ ÀÏ¹Ý °í¾ÐºÐ»êÀåºñ¿¡ ÀÇÇÑ emulsion Å©±âÀÇ Ç¥ÁØÆíÂ÷ (3.8 ~ 14.8) º¸´Ù
ÈξÀ ÀÛ¾Ò´Ù. ÀÌ´Â Microfluidizer¢ç processors ¿¡ ÀÇÇØ Á¦Á¶µÈ nano-emulsion vaccine adjuvant ÀÇ nano-emulsion ÀÇ Å©±â°¡ ¸Å¿ì
±ÕÀÏÇÏ´Ù´Â °ÍÀ» ÀǹÌÇÑ´Ù.
Improved Stability
¹°ÁúÀÇ Å©±â¸¦ ¹Ì¼¼ÇÏ°Ô Ã³¸®ÇÑ emulsion °ú suspension Á¦Ç°µéÀº ÃþºÐ¸®°¡ ÀϾ°Å³ª ħ° µî°ú °°Àº Çö»óÀÌ ÀϾ´Âµ¥
ÀÌ´Â ¸¹Àº ¿¬±¸ÀÚµé°ú »ý»ê´ã´çÀÚµéÀÌ Á÷¸éÇÏ´Â ¸Å¿ì Áß¿äÇÑ ¹®Á¦µéÀÌ´Ù.
ÀÌ·¯ÇÑ ¹®Á¦µéÀÇ ÇØ°áÀº ºÐ»ê.À¯È ÀåºñµéÀÌ ¹°ÁúÀ» ¾î´ÀÁ¤µµ Ãʹ̼¼ÇÏ°Ô ±×¸®°í ¾î´ÀÁ¤µµ ±ÕÀÏÇÏ°Ô ºÐ»ê, À¯È½ÃÅ°´À³Ä¿¡ ´Þ·ÁÀÖ´Ù.
fixed-geometry ¹æ½ÄÀÇ interaction chamber ¸¦ »ç¿ëÇÏ´Â Microfluidizer¢ç processors ´Â ¾î´À Ÿ»ç Àåºñ¿¡ ºñÇØ
°¡Àå ¹Ì¼¼ÇÏ°í ¶Ç °¡Àå ±ÕÀÏÇÑ nano-emulsion À» Á¦Á¶ÇÒ ¼ö ÀÖ´Ù. ±× °á°ú »ý»êµÈ Á¦Ç°ÀÇ ¾ÈÁ¤¼ºÀÌ ¶Ù¾î³ª°í À¯È¿±â°£µµ ÈξÀ ±æ°ÔµÈ´Ù.
Sterile Filtration
Microfluidizer¢ç processors ´Â ´Ù¸¥ ÀÏ¹Ý °í¾ÐºÐ»êÀåºñ º¸´Ù ó¸® pass ¼ö¸¦ Àû°Ô ÇÏ¿©µµ ¿øÇÏ´Â ÀÔÀÚÅ©±â¸¦ ¸¸µé¼ö ÀÖ¾î ¸Å¿ì È¿À²ÀûÀÌ´Ù.
vaccine adjuvant Á¦Á¶¿Í °°Àº application Àº particle size reduction °øÁ¤ ´ÙÀ½¿¡ sterile filtration À» ÇØ¾ß ÇÏ´Â °æ¿ì°¡ Àִµ¥
ÀÌ °æ¿ì Microfluidizer processor ¸¦ ÀÌ¿ëÇÏ¸é ´ëºÎºÐÀÇ ÀÔÀÚÅ©±â°¡ 200nm ÀÌÇÏÀ̹ǷΠ¾ÆÁÖ ÀûÀº ¸éÀûÀÇ filter ¸¦ ÀÌ¿ëÇÏ¿©
È¿À²ÀûÀ¸·Î sterile filtration À» ÇÒ ¼ö ÀÖ´Ù´Â ÀåÁ¡ÀÌ ÀÖ´Ù.
Scalability
Microfluidics »ç´Â Microfluidizer processor ¸¦ ÀÌ¿ëÇÑ Scaleup ¿¡ ´ëÇÑ °á°ú¸¦ º¸ÀåÇÑ´Ù.
Quality Improvements
½ÄÇ° ÈÀåÇ° Á¦Ç°¿¡¼ Åõ¸íÇÑ ¸ð¾ç°ú °°Àº Ư¡µéÀº
Microfluidizer¢ç processors ¸¦ ÀÌ¿ëÇÏ¸é ´õ È¿À²ÀûÀ¸·Î ±¸ÇöÀÌ °¡´ÉÇÏ´Ù.
Nanotechnology in Pharmaceutical Applications
nano-emulsion Àº drug delivery mechanism ¿¡¼ Á¡Á¡ ´õ Áß¿äÇÑ À§Ä¡¸¦ Â÷ÁöÇÏ°í ÀÖÀ¸¸ç Microfluidizer¢ç technology ´Â
ÁÖ»çÁ¦·Î »ç¿ëÇÒ ¼ö ÀÖ´Â ºÒ¿ëÇؼº ÀǾàÇ° °³¹ß¿¡ ¸Å¿ì ÀÌ»óÀûÀÎ ±â¼úÀÌ´Ù.
Microfluidizer¢ç Àåºñ´Â ÀüÅëÀûÀÎ emulsion ±â¹ýÀÌ º»ÁúÀûÀ¸·Î °¡Áö°í ÀÖ´Â solubility, stability ±×¸®°í sterilization °ú °°Àº ÇÑ°èµéÀ»
¶Ù¾î ³ÑÀ» ¼ö ÀÖ´Â Àåºñ¶ó ÇÒ ¼ö ÀÖ´Ù.
¾Æ·¡ ³»¿ëµéÀº Á¦¾à ºÐ¾ß¿¡¼ »ç¿ëµÉ ¼ö ÀÖ´Â nano-technology ¿¡ °üÇØ ¼³¸íÇÏ´Â webinar µéÀÌ´Ù.
Additional References
|
|
|
|